Oral Treatment for Mycobacterium ulcerans Infection: Results From a Pilot Study in Benin

Mycobacterium ulcerans infection is responsible for severe skin lesions in sub-Saharan Africa. We enrolled 30 Beninese patients with Buruli ulcers in a pilot study to evaluate efficacy of an oral chemotherapy using rifampicin plus clarithromycin during an 8-week period. The treatment was well tolera...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2011-01, Vol.52 (1), p.94-96
Main Authors: Chauty, Annick, Ardant, Marie-Françoise, Marsollier, Laurent, Pluschke, Gerd, Landier, Jordi, Adeye, Ambroise, Goundoté, Aimé, Cottin, Jane, Ladikpo, Titilola, Ruf, Therese, Ji, Baohong
Format: Article
Language:English
Subjects:
Administration, Oral
Adolescent
Adult
Aged
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - adverse effects
Antibiotics
Bacterial diseases
Bacterial infections
Benin
Biological and medical sciences
BRIEF REPORT
Buruli Ulcer - drug therapy
Chemotherapy
Child
Child, Preschool
Clarithromycin - administration & dosage
Clarithromycin - adverse effects
Drug Therapy, Combination - methods
Effectiveness studies
Female
Healing
Histology
Human bacterial diseases
Humans
Infections
Infectious diseases
Lesions
Male
Medical sciences
Medical treatment failures
Middle Aged
Mycobacterium ulcerans
Mycobacterium ulcerans - isolation & purification
Oral ulcers
Patients
Pilot Projects
Polymerase chain reaction
Rifampin - administration & dosage
Rifampin - adverse effects
Treatment Outcome
Tuberculosis and atypical mycobacterial infections
Ulcers
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mycobacterium ulcerans infection is responsible for severe skin lesions in sub-Saharan Africa. We enrolled 30 Beninese patients with Buruli ulcers in a pilot study to evaluate efficacy of an oral chemotherapy using rifampicin plus clarithromycin during an 8-week period. The treatment was well tolerated, and all patients were healed by 12 months after initiation of therapy without relapse.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciq072